After hours:
| Previous Close | 14.85 |
| Open | 14.93 |
| Bid | 15.49 x 100 |
| Ask | 15.66 x 100 |
| Day's Range | 14.76 - 16.01 |
| 52 Week Range | 6.40 - 33.13 |
| Volume | |
| Avg. Volume | 315,312 |
| Market Cap | 376.815M |
| Beta (5Y Monthly) | 1.11 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.81 |
| Earnings Date | Jan 23, 2025 - Jan 27, 2025 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 16.50 |
GlobeNewswireCVRx to Present at the Piper Sandler 36th Annual Healthcare Conference
MINNEAPOLIS, Nov. 20, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company, today announced that the management team will present at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, Dec. 4, 2024. The Company is scheduled to present at 3:30 PM Eastern Time the same day via webcast. A live audio webcast of the conference presentation will be available online at the investor relations page of the Company’s website at ir.cvrx.com. Ab
- GlobeNewswire
CVRx Announces Positive Outpatient Payment for Barostim Procedure in 2025
MINNEAPOLIS, Nov. 04, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company, announced today that the Centers for Medicare and Medicaid Services (CMS) assigned the Barostim procedure to New Technology Ambulatory Payment Classification (APC) 1580. The APC payment of approximately $45,000 will continue in 2025, as published in the 2025 Medicare Hospital Outpatient Prospective Payment System (OPPS) final rule. This follows the recent announcement that
